Evaluation of the risk of infection associated with subcutaneous allergen immunotherapy

Questions have recently been raised by regulatory bodies in the United States regarding a potential risk of infections related to subcutaneous allergen immunotherapy (SCIT) injections. In response to a fungal meningitis outbreak from contaminated, compounded injectable medications, the US Food and Drug Administration endorsed the US Pharmacopeia's Pharmaceutical Compounding—Sterility Preparations guidelines as the standard for pharmaceutical compounding in 2013.1 An exemption was granted to allergen extracts as long as they addressed specific procedures that were feasible in an office setting.

http://ift.tt/2mHFdlz